Australia markets closed

Camurus AB (publ) (0RD1.L)

LSE - LSE Delayed price. Currency in SEK
Add to watchlist
495.00+12.09 (+2.50%)
As of 12:28PM BST. Market open.

Camurus AB (publ)

Ideon Science Park
Lund 223 70
46 4 62 86 57 30

Full-time employees213

Key executives

NameTitlePayExercisedYear born
Mr. Fredrik TibergPresident, CEO, CSO & Director12.06MN/A1963
Mr. Jon U. Garay AlonsoChief Financial OfficerN/AN/A1973
Mr. Torsten MalmstromChief Technology OfficerN/AN/A1968
Mr. Rein Piir B.Sc.Vice President of Investor RelationsN/AN/A1958
Ms. Maria LundqvistGlobal Head of Human ResourcesN/AN/A1966
Mr. Markus JohnssonSenior Vice President of R&DN/AN/A1972
Mr. Fredrik JoabssonChief Business Development OfficerN/AN/A1972
Mr. Richard JamesonChief Commercial OfficerN/AN/A1964
Mr. Alberto M. PedroncelliChief Medical OfficerN/AN/A1964
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.


Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden. The company operates as a subsidiary of Sandberg Development AB.

Corporate governance

Camurus AB (publ)’s ISS governance QualityScore as of 1 April 2024 is 2. The pillar scores are Audit: 8; Board: 4; Shareholder rights: 1; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.